Lung Cancer Diagnostics Market Size, Share & Industry Analysis, By Cancer Type (Non-Small Cell Lung Cancer(NSCLC), Small Cell Lung Cancer(SCLC)), By Test (Imaging Tests, Sputum Cytology, Biopsy, Molecular Tests, Other tests), By End User (Hospitals, Specialty Clinics, Others) Others and Regional Forecast, 2024-2032

Lung cancer is caused due to uncontrolled growth of cells, which can lead to development of a mass known, usually known as tumours. Lung cancers can usually initiate in any part of the lung, but the majority of cancers of the lung arise from the cells lining the larger and smaller airways (bronchi and bronchioles); for this reason, lung cancers are also referred as bronchogenic cancers or bronchogenic carcinomas. The major cause of lung cancer is strongly correlated with cigarette smoking, with about 90% of lung cancers arising because of tobacco use. Other causes include the presence of lung disease, prior history of lung cancer, air pollution, individual genetic susceptibility. Symptoms of lung cancer are varied depending upon where and how widespread the tumour is. Some common symptoms of the lung cancer include shortness of breath, headache, coughing up blood, chest pain, dysphagia, etc.

The global lung cancer diagnostic market growth is being driven by the rising prevalence of lung cancer, the introduction of technological advancements with regard to accuracy, and the growing awareness levels amongst the population across all the regions. Moreover, the availability of private & government funds for R&D to develop better tumor diagnostic tools are also projected to drive the growth of the lung cancer diagnostics market during the forecast period. For instance, In June 2019, first in vitro diagnostic immunohistochemistry (IHC) assay was launched by Roche Diagnostics to provide improved detection of lung cancer However, the untoward effects associated with imaging solutions and high cost of diagnosis are anticipated to hinder market growth.

Market Segmentation:

By cancer type, the market is segmented into non-small cell lung cancer NSCLC) and small cell lung cancer (SCLC). By test type, the market is segmented into imaging tests, sputum cytology, biopsy, molecular test, and other tests. By end users, the market is segmemted into hospitals, specialty clinics, and others.

By geographic standpoint, the liver cancer treatmement market is segmented into North America, Europe, Asia Pacific, Latin America and the Middle East & Africa.

Key Players Covered:

Some of the major companies that are present in the lung cancer diagnostics market are F. Hoffmann-La Roche Ltd, Thermo Fisher Scientific, AstraZeneca plc, Illumina Inc., Agilent Technologies, Inc. Qiagen, and others.

Key Insights

• Prevalence of Lung Cancer for Key Countries,2018


• New Product Launches in Lung Cancer Diagnostics Market, by Key Players


• Technological Advancements in Global Lung Cancer Diagnostics market


• Recent Industry Developments Such as Partnerships, Mergers, and Acquisitions

Regional Analysis:

North America is expected to dominate the global lung cancer diagnostics market over the forecast period, followed by Europe. The dominance is majorly attributed to the high market penetration rates of technologically advanced diagnostic products, the rising patient awareness, and the rising smoking prevalence level in the region. Asia Pacific is likely to have a lucrative growth in the lung cancer diagnostics market in the forecast period due to the rising prevalence of lung cancer, and improvement in the research and development of diagnostic tools. Latin America and Middle East America are also expected to have a substantial growth in the lung cancer diagnostics market.

Segmentation

Lung Cancer Diagnostics Industry Developments

• In June 2019, first in vitro diagnostic immunohistochemistry (IHC) assay was launched by Roche Diagnostics with an aim to offer improved detection of lung cancer.


• In May 2019, Biocept launched Target Selector NGS Lung Panel assay. The newly launched devices can be used to perceive and analyse actionable biomarkers which are related with lung cancer.


• In November 2018, Biocartis Group announced a strategic agreement with AstraZeneca with an aim to improve the lung cancer diagnostics in Europe with the help of molecular diagnostic biomarker results in Europe.